The US based cell therapy developer, Aspen Neuroscience, has announced that it will expand its autologous cell therapy manufacturing at its site in San Diego. The expansion will include a new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies.

The site has been built for manufacture and testing of Aspen’s ANPD001, which is an iPSC-derived cell therapy for Parkinson’s Disease (PD). The expansion includes a 14,000 square foot facility with 3,000 square foot of controlled manufacturing space as well as an additional 8,000 square foot for future expansion.